-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

704.O3.6 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity

Symposia: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Autoimmune disorders, Lymphoid Leukemias, ALL, Adult, Autoimmune hemolytic anemia, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune Disorders, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Infusion, Young adult , Human, Study Population, Transplantation (Allogeneic and Autologous)
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
Moderators:
Jennifer N Brudno, MD, National Cancer Institute, National Institutes of Health and Alexandre V. Hirayama, MD, ARRAY(0xdc0235c)
Disclosures:
Hirayama: Juno Therapeutics, a Bristol Myers Squibb Company: Honoraria, Research Funding; Nektar Therapeutics: Research Funding.
4:30 PM

Lori Muffly, MD1, Snegha Ananth, MBBS2, Lindsay Danley3*, Caroline Wagner3*, Diana Kordek3*, Kimi DeNoble4*, Ayesha Fraser3*, Emily Egeler5*, Alfonso Molina, MD, MPH6, Zachary Ehlinger, MS5*, Moksha Desai, MS5*, Hossein Daghagh3*, Ramya Tunuguntla, PhD7*, Annie K. Brown, MS8*, Raquel Ibañez9*, Anne Marijn Kramer, MD, PhD10, Zinaida Good, PhD5, Sally Arai, MD11, Laura Johnston, MD11, Robert Lowsky, MD1*, Andrew R. Rezvani11*, Judith Shizuru11*, Lekha Mikkilineni, MD, MA12, Parveen Shiraz11*, Surbhi Sidana, MD1, Wen-Kai Weng, MD, PhD12, Vanessa E. Kennedy, MD12, Sushma Bharadwaj, MD12, Saurabh Dahiya, MD13, Matthew J. Frank, MD, PhD12, Everett H. Meyer, MD, PhD1, Robert S. Negrin, MD11, Steven A. Feldman, PhD14*, Crystal L. Mackall, MD5, Bita Sahaf11*, David B. Miklos, MD, PhD15 and Melody Smith, MD, MS1

1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
2Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Palo Alto, CA
3Stanford University, Division of Blood and Marrow Transplant and Cellular Therapy, Stanford, CA
4Department of Bone Marrow Transplant and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
6Department of Medicine, Division of Hematology, Stanford University School of Medicine, San Carlos, CA
7Center for Cancer Cell Therapy, Stanford University, Stanford, CA
8Stanford University, Division of Blood and Marrow Transplant and Cellular Therapy, Stanford
9Stanford University School of Medicine, Stanford, CA
10Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Menlo Park, CA
11Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
12Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
13Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Mountain View, CA
14Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA
15Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Palo Alto, CA

4:45 PM

Brynn B. Duncan, MD1*, Sara K. Silbert, MD2, Alexander W. Rankin, MD2*, Bonnie Yates, NP2*, Lauren Little2*, Toni Foley2*, Hao-Wei Wang, MD, PhD3*, Constance M. Yuan, MD, PhD3*, Dana I. Delgado Colon, MD3*, Yanyu Wang4*, Jon Inglefield, PhD4*, John A Ligon, MD2,5*, Hannah W. Song, PhD6*, Steven L. Highfill, PhD6*, Haneen Shalabi, DO2,7, David F. Stroncek, MD, MS8, Naomi Taylor, MD2 and Nirali N. Shah, MD9

1Pediatric Oncology Branch, NCI, Bethesda, MD
2Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD
3Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
4Frederick National Laboratory for Cancer Research, Frederick, MD
5University of Florida, Gainesville, FL
6Center for Cellular Engineering, National Institutes of Health, Bethesda, MD
7Novartis Pharmaceuticals, East Hanover, NJ
8Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, MD
9Pediatric Oncology Branch, NIH, Bethesda, MD

5:00 PM

Xinyu Wan1*, Wenjie Li1*, Jiaoyang Cai2, Xiaomin Yang1*, Liu Yang1*, Jing Yang1*, Tianyi Wang1*, Yue Li3*, Zichao Zhou1*, Xiaoxi Lu4*, Zhiwei Xie3*, Jingbo Shao5*, Meng Su1*, Jing Zhang1*, Juan Qian1*, Kang An1*, Chengjuan Luo1*, Lixia Ding6*, Lili Song1*, Wenhua Shi1*, Jun Lu7*, Cheng Cheng8*, Yanjing Tang6*, Xuefeng Luo, MD9*, Jingyu Li9,10*, Jian Hua, MD9,10*, Benshang Li, MD, PhD6*, Hua Zhang, MD, PhD9,10* and Ching-Hon Pui, MD11

1Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Shanghai Children’s Medical Center, Shanghai, China
2Key Laboratory of Pediatric Hematology & Oncology of the Ministry of Health of China, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
3Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China
4West China Second University Hospital, Sichuan University, Chengdu, China
5Department of Hematology/Oncology, Shanghai Children’s Hospital, Shanghai, China
6Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Shanghai Children's Medical Center, Shanghai, China
7Department of Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, China
8Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
9SPH Biotherapeutics (Shanghai), Limited, Shanghai, China
10SPH Biotherapeutics (HK), Limited, Hong Kong, Hong Kong
11Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

5:15 PM

Ruonan Li1,2,3*, Lele Zhang2,3*, Hong Pan3,4*, Weiwang Li2,3,5*, Jiaxiu Ma1,3*, Linzhu Tian1,2,3*, Yucan Shen1,2,3*, Zhen Gao1,2,3*, Jingyu Zhao, MSc1,2,3*, Ke Huang1,2,3*, Liyun Li1,2,3*, Xiao Yu1,2,3*, Zhexiang Kuang2,3,6*, Meili Ge3,7,8*, Liwei Fang1,2,3*, Lijun Liu1,3*, Weiping Yuan3,9, Shuo Chen1,3*, Lulu Lv, PhD10*, Junhong Song10*, Yi Feng10*, Haiqing Xiong1,3* and Jun Shi, MD1,2,3*

1State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2Red Blood Cell Diseases Center & Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3Tianjin Institutes of Health Science, Tianjin, China
4Red Blood Cell Diseases Center & Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, AL, China
5State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, AL, China
7State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
8State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10Juventas Cell Therapy Ltd, Tianjin, China

5:30 PM

Yunju Ma, MD1*, Qingya Cui1*, Chunxiu Yang, MD1*, Wei Cui1*, Mengyun Li1*, Zheng Li, MD1*, Haiping Dai, MD1*, Liqing Kang2*, Lei Yu2*, Zaixiang Tang3*, Jianxin Fu4*, Min Jiang5*, Depei Wu, MD, PhD1 and Xiaowen Tang1*

1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2Shanghai Unicar-Therapy Bio-Medicine Technology Co.,Ltd, Shanghai, China
3Department of Biostatistics, Soochow University, Suzhou, CHN
4Central Research Laboratory, the First Affiliated Hospital of Soochow University, Suzhou, China., Suzhou, China
5Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, suzhou, China

5:45 PM

Fabian Mueller, MD1, Melanie Hagen, MD2*, Andreas Wirsching, MD2*, Soraya Kharboutli, MD1*, Silvia Spoerl, MD1*, Carlo Tur, MD2*, Tobias Krickau, MD3*, Laura Bucci, MD2*, Christina Bergmann, MD2*, Janina Auth, MD2*, Panayiotis Garantziotis2*, Sebastian Boeltz, MD2*, Sascha Kretschmann, PhD1*, Ingrid Vasova, MD1*, Dimitrios Mougiakakos, MD4, Michael Aigner, PhD1*, Ricardo Grieshaber-Bouyer, MD, PhD2*, Markus Metzler, MD, PhD3*, Simon Voelkl, PhD1*, Georg Schett, MD2* and Andreas Mackensen, MD1*

1Department of Internal Medicine 5 - Hematology and Oncology, University Hospital of Erlangen, Erlangen, Germany
2Department of Internal Medicine 3 – Rheumatology, University Hospital of Erlangen, Erlangen, Germany
3Department of Pediatrics, University Hospital of Erlangen, Erlangen, Germany
4Department of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany

*signifies non-member of ASH